共 91 条
[1]
Gillessen S(2019)Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 Ann Oncol. 30 e3-583
[2]
Omlin A(2000)Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients Hum Pathol 31 578-336
[3]
Attard G(1998)Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone Cancer Metastasis Rev 17 331-223
[4]
Bubendorf L(2013)A. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-3222
[5]
Schöpfer A(2012)A bone marrow toxicity model for Phys Med Biol 57 3207-1316
[6]
Wagner U(2016)Ra alpha-emitter radiopharmaceutical therapy Lancet Oncol 17 1306-e975
[7]
Lange PH(2017)Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial Clin Genitourin Cancer 15 e969-361
[8]
Vessella RL(2019)Factors associated with survival following radium-223 treatment for metastatic castration-resistant prostate cancer Ann Nucl Med 33 351-82
[9]
Parker C(2015)F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies Am J Nucl Med Mol Imaging 5 72-1513
[10]
Nilsson S(2014)(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer Skeletal Radiol 43 1503-7683